Clinical trials
Placebo clinical trials
Below are recruiting placebo clinical trials, each written for real people, not researchers. We’re tracking 5,230 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06884865RecruitingPhase 2
Study of an experimental knee injection for osteoarthritis pain
This study tests a new investigational medicine injected into the knee to see if it is safe and tolerable for people with painful knee osteoarthritis. It may help reduce pain and improve knee function.
Birmingham, AlabamaAges 45–80 - NCT07753122Recruiting
Hydrogen water for chronic fatigue syndrome
This trial tests whether drinking hydrogen water can help with symptoms of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). If you have ME/CFS, this study might show if hydrogen water is a helpful treatment.
Stony Brook, New YorkAges 18–65 - NCT07151391RecruitingPhase 2
Guarana to treat fatigue in neuroendocrine and gynecologic cancers
This study tests whether a natural supplement called guarana can help reduce fatigue in people with neuroendocrine tumors or certain gynecologic cancers. Participants will take guarana and report how their energy levels change.
Salt Lake City, UtahAges 18 years+ - NCT07753603RecruitingPhase 3
Linsitinib for active moderate to severe thyroid eye disease
This study tests an experimental pill (linsitinib) for people with active thyroid eye disease. Participation may help reduce eye bulging and other symptoms, especially if other treatments haven't worked.
Las Vegas, NevadaAges 18 years+ - NCT07168772Recruiting
Probiotic supplement for multiple sclerosis
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
Barcelona, BarcelonaAges 18–60 - NCT07291232RecruitingPhase 1
Study of an injected drug for adults with obesity
This study tests an injected medication called ABBV-295 for adults with obesity. The goal is to see how safe it is and how the body processes it. You may join if you have a BMI between 30 and 45 and are generally healthy, and you haven't been on other weight loss treatments recently.
Anaheim, CaliforniaAges 18–65 - NCT06137365RecruitingPhase 2
Cannabis for Obesity Treatment Study
This study tests whether a cannabis product can help with weight loss in people with obesity. It is for those who have not used cannabis recently and are generally healthy.
Lexington, KentuckyAges 18–65 - NCT07479173Recruiting
How a study ingredient affects protein digestion in healthy adults
This trial tests whether a study ingredient called P24 changes how your body breaks down and uses protein from a meal. It may help researchers understand ways to support muscle health as we age.
Davis, CaliforniaAges 45–75 - NCT04941599RecruitingPhase 2
2-HOBA to improve “good cholesterol” function in FH
This Phase 2 trial tests whether 2-HOBA can improve how “good cholesterol” (HDL) works in people with familial hypercholesterolemia (FH). If HDL works better, it may help lower heart risk markers. You would need to meet several heart, health, and medication-related safety checks.
Nashville, TennesseeAges 18–69 - NCT07502443RecruitingPhase 3
Study of ALKS 2680 for narcolepsy type 2
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
Cullman, AlabamaAges 18–70 - NCT07609108RecruitingPhase 3
Pridopidine to slow Huntington's disease progression
This study tests whether a medication called pridopidine can help slow the progression of Huntington's disease symptoms in adults. Huntington's is a genetic disorder affecting movement, mood, and thinking, and this trial aims to see if pridopidine improves daily functioning and quality of life.
Birmingham, AlabamaAges 23–65 - NCT07381803RecruitingPhase 3
Fexofenadine for heart attack recovery
This trial tests if the allergy medicine fexofenadine can improve recovery after a heart attack. You may qualify if you had a specific type of heart attack (STEMI) within the last week.
Hangzhou, ZhejiangAges 18 years+ - NCT07549256RecruitingPhase 2
Cannabidiol for Pain Relief in Advanced Prostate Cancer
This trial tests whether cannabidiol (CBD), a non-intoxicating cannabis compound, can help relieve pain in patients with advanced prostate cancer that has stopped responding to standard treatments. You would take CBD daily alongside your current morphine pain medication.
GistrupAges Any age - NCT06381180RecruitingPhase 1/Phase 2
Cannabis for Veterans with PTSD
This study is testing whether cannabis can help veterans with PTSD feel better. It is for veterans who have used cannabis before and currently have PTSD symptoms.
Detroit, MichiganAges 19–69 - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Hot Springs, ArkansasAges 18 years+ - NCT06439277RecruitingPhase 3
Tirzepatide for teens with obesity and related health problems
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
Los Angeles, CaliforniaAges 12–17 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT07455383RecruitingPhase 3
Testing ALKS 2680 for adults with narcolepsy type 1
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
Cullman, AlabamaAges 18–70 - NCT07600736RecruitingPhase 2
Safety study of ABS-1230 for children with KCNT1 epilepsy
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
Hackensack, New JerseyAges 1 month–21 years - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Woolloongabba, QueenslandAges 18 years+ - NCT07540897RecruitingPhase 3
Testing ALKS 2680 for narcolepsy type 1
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
Miami, FloridaAges 18–70 - NCT07592689RecruitingPhase 3
DT120 Treatment for Major Depression
This study tests whether a new medication called DT120 can help people with moderate-to-severe depression feel better. You'd take the medication for several weeks while doctors track your mood and symptoms.
Little Rock, ArkansasAges 18–74 - NCT06527391RecruitingPhase 2/Phase 3
Iron and choline for babies with low iron
This study tests whether giving iron and choline (a nutrient important for brain development) can improve brain health in babies with low iron. It is for 5- to 7-month-olds who are still breastfeeding.
Minneapolis, MinnesotaAges 5 months–7 months - NCT06899178RecruitingPhase 2
Atomoxetine for genetic obesity due to MC4R changes
This trial tests a medicine called atomoxetine (Strattera) to help people with a specific genetic form of obesity lose weight. It may be an option if you have a change in the MC4R gene and have not used certain other medications recently.
New York, New YorkAges 6 years+
Hear when a new Placebo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for placebo?
- Yes. Clin2 currently lists 5,230 recruiting placebo studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a placebo trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a placebo trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.